Shanghai Chest Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1957-01-01

Employees: -

Market Cap: -

Website: http://www.shmtppp.com/hospitals/chest

Clinical Trials

To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Phase 2

Conditions: Non-small Cell Lung Cancer Stage IIIA
Radiotherapy

Interventions: Radiation: PORT
Drug: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)

First Posted Date: 2016-11-30

Last Posted Date: 2020-11-13

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 300

Registration Number: NCT02977169

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer

Phase 2

Conditions: NSCLC

Interventions: Radiation: Conventional Fractionated Radiotherapy
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2016-11-29

Last Posted Date: 2016-11-29

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 100

Registration Number: NCT02975609

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Non-small Cell Lung Cancer Stage IIIA
Radiotherapy

Interventions: Radiation: PORT-last
Radiation: PORT-first
Drug: Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)

First Posted Date: 2016-11-28

Last Posted Date: 2024-06-12

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 132

Registration Number: NCT02974426

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Transbronchial Ablation for Peripheral Lung Tumor

Not Applicable

Conditions: Lung Cancer

Interventions: Procedure: Microwave ablation
Procedure: Radiofrequency ablation

First Posted Date: 2016-11-23

Last Posted Date: 2020-02-18

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 60

Registration Number: NCT02972177

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, China

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Phase 2

Conditions: Lung Adenocarcinoma

Interventions: Drug: Pemetrexed plus carboplatin combined with gefitinib
Drug: Gefitinib

First Posted Date: 2016-11-01

Last Posted Date: 2016-11-01

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 300

Registration Number: NCT02951637

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

Phase 2

Conditions: Pulmonary Large Cell Neuroendocrine Carcinoma

Interventions: Drug: etoposide plus carboplatin
Drug: Paclitaxel plus carboplatin

First Posted Date: 2016-10-25

Last Posted Date: 2016-10-25

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 118

Registration Number: NCT02943798

Precision Diagnosis for Intraoperative Frozen Section of Early Stage Lung Cancer

Not Applicable

Conditions: Lung Cancer

Interventions: Device: microscope
Other: immunostaining
Device: NGS

First Posted Date: 2016-10-21

Last Posted Date: 2016-10-27

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 540

Registration Number: NCT02941003

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations

Phase 2

Conditions: SBRT
GM-CSF
NSCLC

Interventions: Drug: two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel
Radiation: SBRT concurrent with GM-CSF

First Posted Date: 2016-10-21

Last Posted Date: 2016-12-01

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 50

Registration Number: NCT02940990

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal Cancer

Phase 2

Conditions: Chemoradiation
Surgery
Esophageal Cancer

Interventions: Radiation: radiotherapy
Procedure: Surgery

First Posted Date: 2016-10-19

Last Posted Date: 2016-10-19

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 50

Registration Number: NCT02938195

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study

Phase 3

Conditions: Non-small-cell Lung Cancer

Interventions: Radiation: 18F-FDG

First Posted Date: 2016-10-19

Last Posted Date: 2016-10-21

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 200

Registration Number: NCT02938546

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy